PDGFRB and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, studies on the effects of nilotinib on bone cells in Ph+ patients receiving nilotinib for treatment of CML have demonstrated that nilotinib potently inhibited osteoblast proliferation through inhibition of the platelet-derived growth factor (PDGFR).